TEVA•benzinga•November 1, 2024 at 07:01 PM

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements In Social Functioning And Quality Of Life In Adults Receiving TEV-'749, A Subcutaneous Long-Acting Injectable As Well As Results Of R

No summary available.

Read the full article from the original source for complete details and context.

Article published on November 1, 2024 by benzinga